Browsing publications by Professor Alan Calvert

Newcastle AuthorsTitleYear
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas2011
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Mike Cole
Professor Ruth Plummer
et al.		Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy2010
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors2010
Professor Alan Calvert
Professor Ruth Plummer
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Amy Quinn
Professor Alan Calvert
et al.		The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy2010
Amy Quinn
Professor Alan Calvert
Professor John Lunec
A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues2009
Professor Alan Calvert
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer2009
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Professor Ruth Plummer
Professor Alan Calvert
et al.		Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis2009
Professor Alan Calvert
Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies2009
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Alan Calvert
et al.		Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
1234567891011121314151617181920...